How key drugs boosted Gilead — and how the Inflation Reduction Act could deliver a ...
Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...
BioSpace4 小时
Anticipating Approval, Gilead Gears Up for Mid-Year Launch for Lenacapavir PrEP
Gilead beat consensus estimates in Q4 with $7.6 billion in revenue, driven largely by its HIV drug Biktarvy and CAR T therapies Trodelvy and Yescarta.
Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024.
FiercePharma5 天
Will Gilead's twice-yearly injection dominate the HIV PrEP market? GSK doesn’t think so
The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...